MA-based Kano Therapeutics, a biotech company for targeted correction of gene-length stretches of DNA through a new class of biomaterial: circular single-stranded DNA has secured $5 million, brings total funding to $7.1 million in seed funding round co-led by The Engine Ventures and VSquared Ventures, with Taihill Venture and Metaplanet also participating.
Read also – Funding Wrap of the Week | American Startups Funding Roundup | August 5 – August 9
These funds will be used in the development of Kano Therapeutics’s GLP standards, process design for clinical-grade production of kilobase ssDNA, and the advancement of the company’s internal and external programs through collaborative drug development.
Read also – [Funding News] CA-based Bardeen Raises $3 Million in Funding
“We believe curing genetic diseases isn’t just a biology problem; it’s an engineering problem,” said Dr. Floris Engelhardt, co-founder and CEO of Kano. “The materials we need to deliver on the full promise of genetic therapies are incomplete. This is why we’re building a ‘one-stop shop’ product development platform for safer DNA payloads at scale. By accessing a new class of gene repair templates, Kano can expand the capabilities of today’s editing techniques, and correct longer stretches of DNA effectively and flexibly.”
“Existing genetic medicines can change a letter – or maybe a word – of genetic information, but Kano is introducing the ability to replace entire sentences and even paragraphs,” said Ann DeWitt, General Partner at The Engine Ventures. “The company’s platform is positioned to have an incredible impact on gene and cell therapy, providing the biomedical ecosystem with an entirely new category of technology that will make targeted, non-viral therapeutic gene insertions a reality,” added Lise Rechsteiner, General Partner at VSquared Ventures.
Kano Therapeutics is engineering the next generation of biomaterials for gene editing. Our platform generates optimized DNA templates aimed at: Breaking down manufacturing bottlenecks, Enabling longer DNA insertions, and Unlocking novel gene editing targets
About Kano Therapeutics
Founded in 2021, Kano Therapeutics is a founder-led biotech startup enabling safe, effective, and flexible correction of gene-length stretches of DNA through a new class of biomaterials.
By building a “one stop shop” product development platform for single-stranded DNA templates that combines manufacturing, application, and computational tools bridge the gap between editing genes and totally replacing them, empowering scientists, labs, and companies with the building blocks they need to cross the chasm to cures.
